Summit Therapeutics’ stock soars as biotech says its cancer drug beat Keytruda in Phase 3 - Endpoints News
endpts.comSubmitted by endpointsnews6292 in business
Hours before America’s biggest cancer conference starts in Chicago, a small biotech may have stolen the show, touting late-stage results in a Thursday afternoon press release that added over $5 billion to its market capitalization — with one major caveat. Sum…